SNAP-8
A cosmetic-facing peptide often discussed in topical anti-wrinkle and expression-line products.
Also referenced as: Acetyl Octapeptide-3
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Acetyl Octapeptide-3
No FDA label signal · 0 trials · 0 PubMed results
There is essentially no indexed clinical or preclinical literature for SNAP-8. Claims rest on user reports and marketing rather than studies.
SNAP-8 has no clinical trials that name it and 0 PubMed-indexed publications and is not FDA-approved.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What SNAP-8 is
SNAP-8, also called acetyl octapeptide-3, is a cosmetic-oriented peptide that shows up in skin-care and anti-wrinkle product lines rather than mainstream medical peptide discussions.
Why it matters
It gives the cosmetic category more depth and helps distinguish dermal-market peptides from the metabolic and recovery compounds that dominate most peptide sites.
Regulatory context
SNAP-8 is not an FDA-approved drug. It belongs in the research and cosmetic-market category rather than any therapeutic category.
Practical reading note
Cosmetic peptides are often marketed with a softer tone than research peptides, but they still benefit from the same basic questions about evidence, formulation, and actual product category.